Intellia Therapeutics NTLA Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$412.69M+20.5% | -$519.02M-7.9% | -$481.19M-1.5% | -$474.19M-77.0% | ||
| $9.78M-4.9% | $10.28M+14.5% | $8.98M+18.5% | $7.57M+9.9% | ||
| $80.22M-48.0% | $154.27M+15.1% | $134.05M+46.7% | $91.4M+94.4% | ||
| -$394.74M-13.1% | -$348.88M+11.5% | -$394.09M-18.2% | -$333.29M-48.1% | ||
| $1.13M-80.5% | $5.78M-58.7% | $13.99M+3.1% | $13.56M+6.3% | ||
| $228.77M+82.2% | $125.57M— | —— | —— | ||
| $131.49M-29.2% | $185.75M+42.5% | $130.32M-77.6% | $582.96M-20.9% | ||
| —— | —— | —— | $416.88M+1,166% | ||
| -$395.87M-11.6% | -$354.66M+13.1% | -$408.07M-17.7% | -$346.85M-45.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Intellia Therapeutics's cash flow data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.